Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice

Neuroendocrinology

Volumn 77, Issue 4, 2003, Pages 223-231

  Ramirez, Andres D ^a   Liu, Xingrong ^a   Menniti, Frank S ^a  

^a PFIZER INC   (United States)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Catecholamines; Gonadal steroids; Neuroprotection; Parkinson's disease; Receptor modulators; Synthetic estrogen

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 17ALPHA ESTRADIOL; DOPAMINE; ESTRADIOL; ESTROGEN RECEPTOR; RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN NUCLEUS; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE MODEL; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; MALE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; MALE; MICE; MICE, INBRED C57BL; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0037531382     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070277     Document Type: Article

References (36)

1. Moghal S, Rajput AH, D'Arcy C, Rajput R: Prevalence of movement disorders in elderly community residents. Neuroepidemiology 1994;13:175-178.
2. Lang AE: Manipulating the dopaminergic system in Parkinson's disease. Phamacol Ther 1987;32:51-76.
3. Langston JW, Irwin I, Ricaurte GA: Neurotoxins, parkinsonism and Parkinson's disease. Pharmacol Ther 1987;32:19-49.
4. Marek K, Seibyl J, Shoulson I, Holloway R, Kieburtz K, McDermott M, Kamp C, Shinaman A, Fahn S, Lang A, Weiner W, Welsh M: Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1660.
5. Ball J: Current advances in Parkinson's disease. Trends Neurosci 2001;24:367-369.
6. Dluzen DE: Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. J Neurocytol 2000;29:387-399.
7. Dluzen DE, McDermott JL, Liu B: Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 1996;18:603-606.
8. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK: Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. I. Systemic administration. J Pharmacol Exp Ther 1994;270:1008-1014.
9. Gerlach M, Riederer P, Przuntek H, Youdim MB: MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol 1991;208:273-286.
10. Greenamyre JT, Sherer TB, Betarbet R, Panov AV: Complex I and Parkinson's disease. IUBMB Life 2001;52:135-141.
11. Wilson ME, Dubal DB, Wise PM: Estradiol protects against injury-induced cell death in cortical explant cultures: A role for estrogen receptors. Brain Res 2000;873:235-242.
12. Alkayed NJ, Harakuni I, Kimes AS, London ED, Traystman RJ, Hurn PD: Gender-linked brain injury in experimental stroke. Stroke 1998;29:159-166.
13. Dubal DB, Kashon ML, Pettigrew LC, Ren JM, Finklestein SP, Rau SW, Wise PM: Estradiol protects against ischemic injury. J Cereb Blood Flow Metab 1998;18:1253-1258.
14. Marder K, Tang MX, Mejia H, Alfaro B, Cote L, Louis E, Groves J, Mayeux R: Risk of Parkinson's disease among first-degree relatives: A community-based study. Neurology 1996;47:155-160.
15. Lyons KE, Hubble JP, Troster AI, Pahwa R, Koller WC: Gender differences in Parkinson's disease. Clin Neuropharmacol 1998;21:118-121.
16. Miller DB, Ali SF, O'Callaghan JP, Laws SC: The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann NY Acad Sci 1998;844:153-165.
17. Dluzen DE, McDermott JL: Estrogen, anti-estrogen and gender: Differences in methamphetamine neurotoxicity. Ann NY Acad Sci 2002;965:136-156.
18. Saunders-Pullman R, Gordon-Elliott J, Parides M, Fahn S, Saunders HR, Bressman S: The effect of estrogen replacement on early Parkinson's disease. Neurology 1999;7:141-149.
19. Ekue A, Boulanger JF, Morissette M, Di Paolo T: Lack of effect of testosterone and dihydrotestosterone compared to 17β-oestradiol in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mice. J Neuroendocrinol 2002;14:731-736.
20. Dluzen DE, McDermott JL, Anderson LI: Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system. Neurotoxicity Res 2001;3:291-300.
21. Callier S, Morissette M, Grandbois M, Di Paolo T: Stereospecific prevention by 17β-estradiol of MPTP-induced dopamine depletion in mice. Synapse 2000;37:245-251.
22. Jones CD, Jevnikar MG, Pike AJ, Peters MK, Black LJ, Thompson AR, Falcone JF, Clemens JA: Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo [b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride (LY 156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. J Med Chem 1984;27:1057-1066.
23. Paxinos G, Franklin KBJ: The Mouse Brain in Stereotaxic Coordinates, 2nd ed. San Diego, Academic Press, 2001.
24. Callier S, Morissette M, Grandbois M, Pelaprat D, Di Paolo T: Neuroprotective properties of 17β-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 2001;41:131-138.
25. Grandbois M, Morissette M, Callier S, Di Paolo T: Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuroreport 2000;11:343-346.
26. Becker JB, Ramirez VD: Sex differences in the amphetamine stimulated release of catecholamines from rat striatal tissue in vitro. Brain Res 1981;204:361-372.
27. Zhou W, Koldzic-Zivanovic N, Clarke CH, De Beun R, Wassermann K, Bury PS, Cunningham KA, Thomas ML: Selective estrogen receptor modulator effects in the rat brain. Neuroendocrinology 2002;75:24-33.
28. Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, Holsboer F: Neuroprotection against oxidative stress by estrogens: Structure-activity relationship. Mol Pharmacol 1997;51:535-541.
29. Green PS, Bishop J, Simpkins JW: 17β-Estradiol exerts neuroprotective effects on SK-N-SH cells. J Neurosci 1997;17:511-515.
30. Green PS, Gordon K, Simpkins JW: Phenolic A ring requirement for the neuroprotective effects of steroids. J Steroid Biochem Mol Biol 1997;63:229-235.
31. Zhang JQ, Cai WQ, Zhou DS, Su BY: Distribution and differences of estrogen receptor beta immunoreactivity in the brain of adult male and female rats. Brain Res 2002;935:73-80.
32. Dubal DB, Zhu H, Yu J, Rau SW, Shughrue PJ, Merchenthaler I, Kindy MS, Wise PM: Estrogen receptor α, not β, is a critical link in estradiol-mediated protection against brain injury. Proc Natl Acad Sci USA 2001;98:1952-1957.
33. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C: Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-1647.
34. Wakeling AE, Valcaccia B, Newboult E, Green LR: Non-steroidal antioestrogens - receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 1984;20:111-120.
35. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW: Effects of rolaxifene on serum lipid and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-1451.
36. Wu X, Glinn MA, Ostrowski NL, Su Y, Ni B, Cole HW, Bryant HU, Paul SM: Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res 1999;847:98-104.